Shop Talk : Oncology Times

An abstract is unavailable.

Source: journals.lww.com

Categories: Oncologists1, General Medicine News

Tweets with this article

Oncology Times

Daniel Siegwart, PhD, has been selected as a fellow of the National Academy of Inventors (NAI) in recognition of his efforts in materials chemistry to enable targeted nanoparticle delivery of genomic medicines. https://t.co/NBDl4r1nmV https://t.co/cfNreR04KC

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.

OncLive.com January 10, 2025

US Surgeon General calls for cancer warning labels on alcohol

As one of his final acts under the outgoing administration of US President Joe Biden, Surgeon General Vivek Murthy has called for cancer warnings to…

The Lancet Oncology January 10, 2025

Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer

Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.

OncLive.com January 10, 2025

Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms

Alex Rampotas, MBBS, MRCP, University College London, London, UK, and Zoë Wong, BSc, University of Oxford, Oxford, UK, discuss the development and evaluation of a…

VJHemOnc January 10, 2025

Pharma & Biotech Alliance Manager Position At EORTC

The Pharma & Biotech Alliance manager is a Medical Doctor who works under the hierarchical supervision of the Headquarters Director.

EORTC January 10, 2025

Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer

Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast…

OncLive.com January 10, 2025